You are here
Influence of vascular comorbities and race on erectile dysfunction after prostate cancer radiotherapy.
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).
Background: Vascular comorbidities (VC’s) [hypertension (HTN), diabetes (DM) and/or hyperlipidemia (HL)] are known factors related to erectile dysfunction (ED) prior to radiotherapy (XRT). We have undertaken this study to understand the influence of VC’s on post-XRT ED incidence, and to further characterize ED incidence by racial groups. Methods: We reviewed the charts of 732 prostate cancer patients [267 white (W) and 465 African American (AA)] who received XRT [external beam radiotherapy (EBRT) and/or brachytherapy (BT)] with or without use of hormone therapy between 1999 and 2010. The number of pre-XRT VC’s (0, 1, 2, or 3) was determined by medical history and medication list. ED (defined by use of erectile aids or by documentation of moderate or high sexual dysfunction on patient history) was determined pre-XRT as well as 1, 6, and 12 months post-XRT and compared by follow-up interval since XRT, by number of VC’s, and by race in each case using the two sample proportion test. Results: ED incidence progressively increased with time from 22% pre-XRT to 52% 12 months post-XRT (p<0.001). Additionally, ED incidence increased with increasing of number of VC’s – 12-month incidences between patients with 0 vs 2 (p=0.024), 0 vs 3 (p<0.